GME Transparency Act of 2026
Summary
H.R. 8942 (GME Transparency Act) is an early-stage bill requiring hospitals to report resident citizenship data to maintain Medicare GME funding. It authorizes no spending and is in the earliest legislative step – referred to committees. No direct market impact for any public company. The bill imposes compliance and reporting costs, but hospitals absorbing those are not publicly traded entities here, and the data has no pricing or revenue mechanism for any traded sector.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.H.R. 8942 is a procedural reporting requirement with zero authorized spending.
- 2.No publicly traded company faces material revenue or cost impact from this bill.
- 3.Legislative momentum is minimal: single sponsor, early stage, no companion bill.
Market Implications
No equity or sector implications. This bill does not alter revenue, costs, or competitive dynamics for any public company. The healthcare sector is unaffected. Investors should not adjust positions based on this filing.
Full Analysis
On May 20, 2026, Rep. Steube (R-FL) introduced H.R. 8942, the 'GME Transparency Act of 2026.' The bill amends the Social Security Act to condition Medicare direct graduate medical education (GME) payments on hospitals submitting deidentified residency citizenship data to HHS, which then reports aggregates to Congress. The bill is in the earliest legislative stage: referred jointly to Ways and Means and Energy and Commerce committees. No hearings, markups, or further actions have occurred.
The bill authorizes zero new funding. The mechanism is a compliance condition on existing Medicare GME payments — hospitals that do not report lose eligibility for that payment. The funding for GME is already authorized under Medicare Part A; this bill does not increase or decrease total GME spending. There is no private-sector funding, no contract vehicle, and no tax credit.
Given the bill's limited scope – administrative reporting requirements on teaching hospitals – there is no material revenue or cost impact on any publicly traded company in the sectors represented in the provided financial data (energy, healthcare, etc.). Hospitals affected are either non-profits, government-owned, or if for-profit (e.g., HCA, THC), the compliance cost is de minimis relative to their revenue and the bill lacks any competitive or pricing mechanism. Healthcare tickers like HCA, THC, UHS, or diagnostic/lab companies are not materially affected — this is a reporting requirement, not a change in reimbursement rates, patient volume, or care delivery. No ticker from the energy set has any connection.
Legislative probability of passage is low at this stage — single sponsor, junior member (no committee chair), and referred to two committees with jurisdiction overlaps that require sequential or joint action. A companion bill has not been introduced in the Senate. The 119th Congress has 8 months remaining; this bill is unlikely to advance without broader immigration-focused legislation as a vehicle. Even if passed, the impact is purely administrative for affected hospitals.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Executive Order: Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.